Ann: PAT DX3 Crosses Blood Brain Barrier in Healthy Animals, page-3

AT-DX3 appears to out-perform antibodies specifically developed by other companiesfor the delivery of payloads to brain tissue. Unlike deoxymabs, none of these other antibodies areable to deliver their payloads into the cell and the cell nucleus. These properties open up a range ofapplications for using deoxymabs to deliver small molecule therapeutics and gene editingtechnologies directed to various neurological targets and conditions.

This is great news. Each success is one step closer to international adoption of Patrys' anti cancer therapies.

An investor has to be very patient and be prepared to wait years for the company to reach its full potential.